Skip to main navigation Skip to search Skip to main content

Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain

  • Thomas H. Burkey
  • , Raymond M. Quock
  • , Paul Consroe
  • , Frederick J. Ehlert
  • , Yoshiaki Hosohata
  • , William R. Roeske
  • , Henry I. Yamamura

Research output: Contribution to journalArticlepeer-review

Abstract

We measured (-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol (CP 55,940)-, (-)11-OH-Δ8-tetrahydrocannabinol-dimethylheptyl (HU-210)-, anandamide- and Δ9-tetrahydrocannabinol-stimulated G protein activation in mouse brain using the [35S]GTPγS functional assay. The K(i) values for these drugs were determined by agonist competition binding with the cannabinoid CB, receptor antagonist [3H] N-(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H -pyrazole-3-carboxamidehydrochloride ([3H]SR141716A). This information was used to calculate the efficacy for drug stimulation of G protein activity, The rank order of efficacy was CP 55,940 > HU-210 > anandamide > Δ9-tetrahydrocannabinol with the latter two drugs being partial agonists. Since efficacy values relate receptor occupancy to functional responses, we believe efficacy values are a better measure of drug-mediated functional responses compared with measurements of drug potency.

Original languageEnglish (US)
Pages (from-to)295-298
Number of pages4
JournalEuropean Journal of Pharmacology
Volume336
Issue number2-3
DOIs
StatePublished - Oct 8 1997
Externally publishedYes

Keywords

  • Brain
  • Cannabinoid receptor
  • Cannnbinoid
  • Drug efficacy
  • Mouse
  • Partial agonist
  • Tetrahydrocannabinol

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain'. Together they form a unique fingerprint.

Cite this